By Fineline Cube 
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with Regeneron Pharmaceuticals Inc. (Nasdaq: REGN), granting the US-based biopharmaceutical company exclusive rights to develop, manufacture, and commercialize HS-20094 globally, excluding mainland China, Hong Kong, and Macau.
Financial Terms
Under the agreement, Hansoh will receive an upfront payment of USD 80 million. The company is also eligible for development, regulatory, and commercial milestone payments totaling up to USD 1.93 billion, along with double-digit royalties.
HS-20094 Development
HS-20094 is an investigational GLP-1/GIP dual receptor agonist currently in Phase III clinical study in China. The drug has demonstrated positive efficacy and safety data from multiple Phase II trials, highlighting its potential as a significant therapeutic option.-Fineline Info & Tech